Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (HERMES and AURA) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 48 mL vs. placebo (p<0.0001) and significantly reduced the rate of

Read the full 328 word article

User Sign In